Cadila Pharma is a trusted partner to over 25,000 gynaecologists and specialists across India. Known for its iconic Haem-Up range and path-defining therapies in women’s health, we have been at the forefront of haematology, reproductive health, infertility management, pain relief, and supportive therapies.
India faces a complex landscape of women’s health challenges across reproductive needs, metabolic shifts, and critical maternal risks
Over 53% of Indian women suffer from anaemia, making it a critical public health challenge. Iron deficiency affects maternal and fetal health, productivity, and quality of life.
Affects an estimated 25 million Indian women, often undiagnosed, leading to chronic pelvic pain, infertility, and emotional distress.
Nearly 1 in 5 women of reproductive age are impacted by PMOS. Infertility prevalence is around 10–14% in urban couples, with rising IVF demand.
Nearly 50% of pregnancies in India are considered high-risk, impacting maternal and fetal health outcomes. Luteal phase defects and pregnancy support requirements further underline the need for specialised maternal care.
Our therapeutic focus
We have established our presence in the segments of gynaecology and obstetrics with an exhaustive range.
India carries the largest global burden of anaemia, with more than 57 million pregnant women and adolescent girls affected. We lead this space with a comprehensive iron portfolio:
Conditions such as threatened miscarriage, recurrent pregnancy loss, and the need for luteal phase support and pregnancy maintenance also continue to impact women across different stages of reproductive health. We address these challenges through:
India witnesses nearly 2.5–3 million IVF cycles annually, reflecting rising infertility concerns. As per WHO data, PMOS (PCOS) is the most common cause of anovulation among women globally and a leading cause of infertility. We support both natural and assisted conception with:
Our reach extends into stress management, urology, and nutrition:
Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication.
Reference - NFHS-5
Reference - Indian Centre for Endometriosis
Reference - Science Direct, PMC (National Center for Biotechnology Information)
Reference - Science Chronicle
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
